AAN 2021 | DMTs and risk for severe COVID-19 in multiple sclerosis patients

Maria Pia Sormani, PhD, University of Genoa, Genoa, Italy, describes the project that collected and analyzed data from three thousand patients with multiple sclerosis (MS) that developed COVID-19. From this cohort, two thousand patients were from Italy. Besides the known demographic and clinical risk factors for severe COVID-19 (age, sex, presence of co-morbidities), the study aimed to establish any risk factor associated with MS disease modifying therapies (DMTs). The results from patients receiving anti-CD20 and interferon therapies are discussed. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.